All Updates

All Updates

icon
Filter
Partnerships
VantAI signs USD 674 million GenAI deal with Bristol Myers Squibb
AI Drug Discovery
Feb 13, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 13, 2024

VantAI signs USD 674 million GenAI deal with Bristol Myers Squibb

Partnerships

  • GenAI drug discovery company VantAI has forged a strategic collaboration with Bristol Myers Squibb (BMS) to develop new molecular glues for various therapeutic targets.

  • As part of the agreement, VantAI is eligible to receive up to USD 674 million as discovery, development, clinical, regulatory, and sales milestone payments, as well as specific, tiered royalty payments. The agreement also enables the option to broaden the partnership to more therapeutic programs from BMS.

  • The collaboration will combine VantAI's geometric deep learning technologies and BMS’ protein degradation expertise to develop molecular glues, which help stabilize the interaction between two proteins. 

  • Founded in 2019, VantAI integrates GenAI with drug discovery to develop computational models that reveal hidden connections between molecules, targets, and diseases, thereby making protein interactions programmable. The company uses geometric deep learning platforms to focus on induced proximity modulators, which are designed to unlock the full potential of proximity modulator modalities for drug discovery. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.